drugset / Trial / NCT00427219

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT00427219

Phase 2 Completed 74 enrolled Spectrum Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

Timeline

Start
2007-01-23
Primary completion
2008-02-27
Completion
2008-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Ozarelix Protein / enzyme biologic 15 mg Intramuscular